Tiziana life sciences to file alzheimer's ind for intranasal foralumab in q2 2023

New york, april 20, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced its plan to submit an ind for intranasal foralumab in patients with mild to moderate alzheimer's disease in q2 2023.
TLSA Ratings Summary
TLSA Quant Ranking